NFKB1 and breast cancer: Cezanne has been associated with tumour progression, namely in breast cancer (Pareja et al., 2012), and it has also been linked to deregulated NF-κB signalling in the context of inflammation (Enesa et al., 2008; Hu et al., 2013; Luong et al., 2013).